Drugs / TAK-853
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06390995 | May 2024 → Apr 2025 overdue | ovarian cancer | Takeda | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAK-853 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06390995 ↗ |
| Route | Intravenous | “TAK-853 intravenous injection” NCT06390995 ↗ |